The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes
Open accessAbstract
Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes Floris Alexander van de LaarRadboud University Nijmegen Medical Centre, Department of General Practice, Nijmegen, The NetherlandsAbstract: Alpha-glucosidase inhibitors (AGIs) are drugs that inhibit the absorption of carbohydrates from the gut and may be used in the treatment of patients with type 2 diabetes or impaired glucose tolerance. There is currently no evidence that AGIs are beneficial to prevent or delay mortality or micro- or macrovascular complications in type 2 diabetes. Its beneficial effects on glycated hemoglobin are comparable to metformin or thiazolidinediones, and probably slightly inferior to sulphonylurea. In view of the total body of evidence metformin seems to be superior to AGIs. More long-term studies are needed to study the effects of AGIs compared to other drugs. For patient with impaired glucose tolerance AGIs may prevent, delay or mask the occurrence of type 2 diabetes. A possible beneficial effect on cardiovascular events should be confirmed in new studies.Keywords: alpha-glucosidase inhibitors, type 2 diabetes mellitus, impaired glucose tolerance
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Metformin monotherapy for type 2 diabetes mellitus
Saenz, A., Fernandez-Esteban, I., Mataix, A., Ausejo Segura, M., Roqué i Figuls, M., & Moher, D. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002966.pub3 · Cited by 308
RetractedReduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Hao (2015) · doi:10.1002/14651858 · Cited by 11,321
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 2×
“With life-style modifi cations, a relative-risk reduction (RRR) in the progression to DM2 of 58% may be achieved (Tuomilehto et al 2001).”
BackgroundTurner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Cited by
The α-amylase and α-glucosidase inhibitory effects of Irish seaweed extracts
Lordan, S., Smyth, T. J., Soler-Vila, A., Stanton, C., & Ross, R. P. (2013) · Food Chemistry · doi:10.1016/j.foodchem.2013.04.123 · Cited by 439
Etxeberria, U., de la Garza, A. L., Campión, J., Martínez, J. A., & Milagro, F. I. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.664134 · Cited by 395
Poovitha, S., & Parani, M. (2016) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-016-1085-1 · Cited by 307
Mohamed Sham Shihabudeen, H., Hansi Priscilla, D., & Thirumurugan, K. (2011) · Nutrition & Metabolism · doi:10.1186/1743-7075-8-46 · Cited by 163
Metadata
- Authors
- Laar, F.
- Venue
- Vascular Health and Risk Management
- Publisher
- Informa UK Limited
- Published
- 2008-12
- Volume
- Volume 4
- Issue
- 6
- Pages
- 1189-1195
- ISSN
- 1176-6344 (ISSN-L)
- 1178-2048
- OpenAlex
- W1479698458
- Cited by
- 360
- References
- 44
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes. https://app.cochat.ai/papers/10.2147/vhrm.s3119
- The paper
- Laar, F. (2008). Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes. Vascular Health and Risk Management. https://doi.org/10.2147/vhrm.s3119
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.